Biocryst Pharmaceuticals INC Form 4 insider transactions

BioCryst Pharmaceuticals reports a stock grant and option award to Director Jill C. Milne.

Steven K. Galson, a Director at BioCryst Pharmaceuticals, Inc., received a grant of Restricted Stock Units and stock options.

Director Alan G. Levin of BioCryst Pharmaceuticals received a grant of restricted stock units and stock options, as disclosed in a Form 4 filing.

Director Frank Steven of BioCryst Pharmaceuticals received a grant of restricted stock units and stock options as part of the company's non-employee director compensation policy.

BioCryst Pharmaceuticals reports a stock grant and option award to Director Machelle Sanders.

BioCryst Pharmaceuticals reports a stock grant and option award to Director Vincent Milano, reflecting compensation and alignment with company performance.

BioCryst Pharmaceuticals reports a stock grant and option award to Director Jon P. Stonehouse.

Amy E. McKee, a Director at BioCryst Pharmaceuticals, received grants of Restricted Stock Units and stock options.

Theresa Heggie, a Director at BioCryst Pharmaceuticals, reported transactions involving restricted stock units and stock options.

Biocryst Pharmaceuticals Director Jill C. Milne acquired 1,262 shares of common stock on May 29, 2026, as a substitute for her quarterly board member retainer.

Biocryst Pharmaceuticals Director Jon P. Stonehouse acquired 631 shares of common stock through a retainer compensation plan.

Biocryst Pharmaceuticals Director Amy E. McKee acquired 631 shares of common stock on May 29, 2026, as part of her board member retainer.

Biocryst Pharmaceuticals Director Vincent Milano acquired 1,122 shares of common stock for $8.91 per share, as reported in a Form 4 filing.

Director Frank Steven acquired 1,262 shares of BioCryst Pharmaceuticals common stock valued at $8.91 per share as a substitute for his quarterly cash board member retainer.

Director Amy E. McKee reported a sale of BioCryst Pharmaceuticals Inc. common stock valued at approximately $100,000.

Chief Legal Officer Alane P. Barnes exercised options and sold 62,500 shares of BioCryst Pharmaceuticals common stock.

Sandeep Menon, Chief R&D Officer at BioCryst Pharmaceuticals, received inducement grants of restricted stock units and employee stock options.

BIOCRYST PHARMACEUTICALS Director Theresa Heggie exercised stock options and subsequently sold an equal number of common shares on March 20, 2026.

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, executed a pre-planned sale of 150,000 common shares following the exercise of stock options.

BioCryst Pharmaceuticals Director Vincent Milano acquired 848 shares of common stock at $8.75 per share, partially in lieu of cash board retainers.

BioCryst Pharmaceuticals Director Steven Frank acquired 1,285 shares of common stock at $8.75 per share, opting for equity over his quarterly cash board retainer.

BIOCRYST PHARMACEUTICALS Director Amy E McKee acquired 642 shares of common stock on February 27, 2026, as part of her board compensation.

BioCryst Pharmaceuticals director Jill C. Milne acquired common stock and stock options following a merger and through director compensation policies.

BioCryst Pharmaceuticals CEO Jon P. Stonehouse reported the withholding of 61,793 common shares for tax obligations related to vested restricted stock units.

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, reported the sale of common stock and shares withheld for taxes, both executed under a pre-arranged 10b5-1 trading plan.

BioCryst Pharmaceuticals' President and CCO, Charles K. Gayer, increased his direct beneficial ownership of common stock through the exercise of employee stock options.

BioCryst Pharmaceuticals CEO Jon Stonehouse gifted 20,000 shares of common stock to two irrevocable family trusts on December 18, 2025.

BioCryst Pharmaceuticals' President and CCO, Charles Gayer, received significant equity awards, including 471,000 restricted stock units and 986,950 stock options, on December 17, 2025.

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, reported the acquisition of 121,700 restricted stock units and 255,050 employee stock options.

BioCryst Pharmaceuticals' Chief Financial Officer, Babar Ghias, was granted restricted stock units and employee stock options as part of his annual compensation.